Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Olbetam

Known as: Olbemox 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background Acute inflammation, and subsequent release of bacterial products (e.g. LPS), inflammatory cytokines, and stress… Expand
Is this relevant?
2014
2014
  • 2014
  • Corpus ID: 34850302
4.1. Therapeutic indications Olbetam is indicated as alternative or adjunct treatment to reduce triglyceride levels in patients… Expand
Is this relevant?
2000
2000
32 patients with hypertriglyceridemia, excessive hypertriglyceridemia, and combined hyperlipidemia, were treated with the… Expand
Is this relevant?
2000
2000
The interrelation was studied of processes of lipid peroxidation (LPO), the antioxidant system (AOS) with the level of endogenous… Expand
Is this relevant?
1995
1995
L'acipimox (Olbetam®), commercialise recemment par la firme Pharmacia, est un nouveau medicament hypolipidemiant, different des… Expand
Is this relevant?
1995
1995
The effect of Olbetam on serum lipid and lipoproteins was studied in 30 diabetic patients with hyperlipidemia in four weeks trial… Expand
Is this relevant?
1994
1994
BACKGROUND Hypertriglyceridaemia associated with low HDL-concentrations is considered an independent risk factor of ischaemic… Expand
Is this relevant?
1991
1991
The objective of this work was to test in type II diabetics with hyperlipoproteinaemia the action of a new analogue of nicotinic… Expand
Is this relevant?
1990
1990
Twenty-one patients with type II hyperlipidaemia were treated with the nicotinic acid analogue, acipimox (Olbetam; Farmitalia… Expand
Is this relevant?